
Physicians and medical boards may have to reconsider decades of cardiogenic shock treatment after the highly anticipated IABP-Shock study found no significant benefit in using intra-aortic balloon pump therapy in heart attack patients.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Physicians and medical boards may have to reconsider decades of cardiogenic shock treatment after the highly anticipated IABP-Shock study found no significant benefit in using intra-aortic balloon pump therapy in heart attack patients.
German doctors have adopted transcatheter aortic valve implantation faster than any other country, according to researchers attending the European Society of Cardiology Congress in Munich.
Analyses of the country’s German Aortic Valve Registry suggest that, although about half of all elderly patients are receiving TAVI therapy, doctors are primarily recommending the procedure for high-risk patients, as advised.
This year’s European Society of Cardiology Congress in Munich, Germany, hosted a fleet of new studies and technologies, but renal denervation hogged the spotlight with no less than 5 research teams presenting evidence of the healing powers of the nerve-deadening procedure.
Teams from Germany, the Czech Republic, France and Australia presented positive findings for renal denervation in treating hypertension better than drugs, improving physical and mental health and reducing stiffness in arteries.
Medtronic Inc. (NYSE:MDT) touted the latest results from studies of its CoreValve transcatheter aortic valve implantation system, which is two years behind competitor Edwards Lifesciences Corp. (NYSE:EW) in the U.S. market, at the European Society of Cardiology Congress 2011 conference in Paris today.